Biotech developing bezuclastinib, a precision KIT-inhibitor drug for systemic mastocytosis and gastrointestinal stromal tumors.
Biotech developing bezuclastinib, a precision KIT-inhibitor drug for systemic mastocytosis and gastrointestinal stromal tumors.
Has no product to sell yet, so spending is funded by investors' money rather than customers. Everything rests on one drug, bezuclastinib, in trials for a rare blood-cell disorder, systemic mastocytosis, and for gastrointestinal stromal tumors, and on the regulatory decisions that follow.
Moat: narrow (IP / patents). A selective KIT D816V inhibitor with a differentiated safety profile versus approved competitors in a niche rare-disease market.
Headquarters: Cambridge, Massachusetts, US · Founded: 2016 · Employees: 258
Size Cogent Biosciences (COGT) is a United States Health Care company (Biotechnology) with a market value of $4.84B, the 1196th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.81 on 18 Nov 2026.
Performance Over six months the shares fell 15.5%, against +1.5% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.
Credit Cogent Biosciences has 1 bond outstanding ($230M).
Short interest Short interest is 10.0% of the free float (30 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$4.95M | -$4.62M | -$4.40M | -$3.59M | -$5.88M |
| EBITDA | -$418M | -$329M | -$272M | -$205M | -$142M |
| Net income | -$408M | -$329M | -$256M | -$192M | -$140M |
| Free cash flow | -$326M | -$266M | -$208M | -$156M | -$126M |
| Capital expenditure | $1.74M | $1.55M | $573,000 | $2.80M | $6.86M |
| Total debt | $244M | $239M | $17.5M | $18.9M | $19.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Cogent Biosciences COGT | $4.84B | -16% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
| ONO Pharmaceutical 4528.T | $7.33B | -2% | -2% | 22% | 2.1× | -6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COGT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.0% | -5.3% | 8th lowest of 21 |
| 6-month return | -15.5% | +1.5% | 5th lowest of 21 |
| Distance from 52-week high | -36.4% | -31.9% | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 4.8× | 25.9% | +16.4% |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 12.4× | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
Cogent Biosciences has 1 bond outstanding with $230M face value.